CSL 0.40% $300.58 csl limited

News: CSL Seqirus Receives FDA Approval For FLUAD® QUADRIVALENT

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Feb 24 (Reuters) - CSL Ltd (CSL) :

    • SEQIRUS RECEIVES FDA APPROVAL FOR FLUAD® QUADRIVALENT (INFLUENZA VACCINE, ADJUVANTED) FOR ADULTS 65 YEARS AND OLDER
 
watchlist Created with Sketch. Add CSL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.